Updates

EKF Diagnostics

October 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

EKF has announced sales for H1 that were up 71% to Â£12.7m, helped by the acquisition of Stanbio (7% organic). Sales were slightly short on forecasts although profits still have met market expectations mainly due to higher than expected sales of reagents. The operating profit for the period was Â£0.34m with an adjusted EBITDA of Â£1.4m.The year saw delays to launches of both its low cost diabetes monitor, Quo-Lab, for sale in emerging markets and the HemoPoint H2 blood testing instruments and cuvettes which are being marketed by Alere in the US, although both are now on the market and gaining traction. Quo-Lab launched in early July and has sold 290 devices, whilst HemoPoint H2, which was only officially launched by Alere in ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Staffline - Very stong H2 likely

Advanced Computer Software

EKF Diagnostics (January 2015)

EKF Diagnostics (October 2014)

EKF Diagnostics (June 2014)

EKF Diagnostics - Three acquisitions in a month (April 2014)

EKF Diagnostics (March 2014)

EKF Diagnostics (October 2013)

EKF Diagnostics (April 2013)

EKF - Forecasts upgraded again (April 2012)

EKF DIagnostics (October 2011)

EKF - Second large diagnostic deal sends EKF full square into the US market (July 2011)

EKF Diagnostics (December 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X